Top 10 Fast-growings companies in PCSK9 Inhibitors by Most Patent Filing In 5 Years in the United States in 2021 – Discovery

Free Trial

The PCSK9 Inhibitors top 10 is Discovery PatSnap’ annual ranking of the top 10 Most Patent Filing In 5 Years PCSK9 Inhibitors Fast-growings in the United States. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2021, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.

Ranking Year:

Region:

Ranking:

1	Regeneron Pharmaceuticals, Inc.	New York, United States	Monoclonal antibody,Clinical trial,Cholesterol, ...[+2]	Patent: 48
2	Amgen, Inc.	California, United States	Health care,Biopharmaceutical,TUMOR NECROSIS FACTOR BLOCKER, ...[+2]	Patent: 16
3	The Brigham & Women's Hospital, Inc.	Massachusetts, United States	Health care,Mitral valve surgery,Health equity, ...[+2]	Patent: 5
4	Duke University	North Carolina, United States	Style guide,Typeface,Medicine, ...[+2]	Patent: 4
5	STARTUP Dogma Therapeutics, Inc.	Massachusetts, United States	PCSK9,Cardiovascular agent,Biophysics, ...[+2]	Patent: 3
6	Ra Pharmaceuticals, Inc.	Massachusetts, United States	Medicine,Health care,Drug class, ...[+2]	Patent: 3
7	Genentech, Inc.	California, United States	Biotechnology,Biology,Medicine, ...[+2]	Patent: 2
8	Merck Sharp & Dohme Corp.	New Jersey, United States	Prescription drug,Medicine,Stroke, ...[+2]	Patent: 1
9	Merck & Co., Inc.	New Jersey, United States	Health care,Biopharmaceutical,Drug, ...[+2]	Patent: 1
10	CymaBay Therapeutics, Inc.	California, United States	Drug,Gout,Drug development, ...[+2]	Patent: 1